We are live on ! Find out more
DP

Diadema Partners Portfolio holdings

AUM $791M
1-Year Est. Return 245.83%
This Fund
S&P 500
This Quarter Est. Return
+47.67%
1 Year Est. Return
+245.83%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$391M
AUM Growth
+$62.8M
Cap. Flow
-$30.5M
Cap. Flow %
-7.81%
Top 10 Hldgs %
31.01%
Holding
170
New
75
Increased
15
Reduced
22
Closed
40

Top Buys

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$13.9M
2
BMY icon
Bristol-Myers Squibb
BMY
+$6.07M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$5.32M
4
ASND icon
Ascendis Pharma A/S
ASND
+$5.14M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$4.07M

Top Sells

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$14.5M
2
LLY icon
Eli Lilly
LLY
+$11M
3
TGTX icon
TG Therapeutics
TGTX
+$10.2M
4
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$9.76M
5
SLNO
Soleno Therapeutics
SLNO
+$7.92M

Sector Composition

Rank Sector Weight
1 Miscellaneous 63.28%
2 Healthcare 36.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNA icon
51
PUT
Moderna
MRNA
$61.5B
$2.58M 0.66%
100,000
– –
REPL icon
52
CALL
Replimune Group
REPL
$1.23B
$2.57M 0.66%
+612,300
New +$3.91M
APGE
53
DELISTED
Apogee Therapeutics
APGE
$2.55M 0.65%
64,250
+53,678
+508% +$2.05M
TERN
54
DELISTED
Terns Pharmaceuticals
TERN
$2.43M 0.62%
323,159
+63,307
+24% +$404K
ABUS icon
55
CALL
Arbutus Biopharma
ABUS
$991M
$2.34M 0.6%
+516,300
New +$1.9M
ARDX icon
56
Ardelyx
ARDX
$880M
$2.2M 0.56%
+400,000
New +$2.17M
CORT icon
57
PUT
Corcept Therapeutics
CORT
$12.1B
$2.2M 0.56%
26,500
-73,700
-74% -$5.33M
TGTX icon
58
TG Therapeutics
TGTX
$8.77B
$2.19M 0.56%
60,748
-310,700
-84% -$10.2M
GOSS icon
59
CALL
Gossamer Bio
GOSS
$74.1M
$2.17M 0.55%
10,310
– –
CAPR icon
60
CALL
Capricor Therapeutics
CAPR
$524M
$2.16M 0.55%
+300,000
New +$2.21M
ALKS icon
61
Alkermes
ALKS
$7.35B
$2.16M 0.55%
+72,079
New +$2.03M
ACAD icon
62
CALL
Acadia Pharmaceuticals
ACAD
$4.64B
$1.9M 0.49%
89,000
+100
+0.1% +$2.37K
ROIV icon
63
Roivant Sciences
ROIV
$29B
$1.82M 0.46%
+120,000
New +$1.49M
URGN icon
64
UroGen Pharma
URGN
$2.12B
$1.8M 0.46%
90,000
-60,000
-40% -$1.08M
MBX
65
CALL
MBX Biosciences
MBX
$3.01B
$1.75M 0.45%
+100,000
New +$1.34M
ALT icon
66
CALL
Altimmune
ALT
$621M
$1.75M 0.45%
463,000
-799,900
-63% -$3.09M
TERN
67
CALL
DELISTED
Terns Pharmaceuticals
TERN
$1.69M 0.43%
225,200
+64,300
+40% +$411K
OCUL icon
68
CALL
Ocular Therapeutix
OCUL
$2.19B
$1.6M 0.41%
136,700
– –
TECX
69
CALL
Tectonic Therapeutic
TECX
$531M
$1.57M 0.4%
+100,000
New +$2.06M
SMMT icon
70
CALL
Summit Therapeutics
SMMT
$13.9B
$1.54M 0.39%
74,700
– –
PCRX icon
71
Pacira BioSciences
PCRX
$981M
$1.52M 0.39%
58,926
– –
NVAX icon
72
CALL
Novavax
NVAX
$1.64B
$1.5M 0.38%
+173,500
New +$1.35M
COGT icon
73
Cogent Biosciences
COGT
$5.5B
$1.4M 0.36%
97,813
-294,400
-75% -$3.49M
NVO
74
Novo Nordisk
NVO
$192B
$1.39M 0.35%
+25,000
New +$1.46M
HRMY icon
75
PUT
Harmony Biosciences
HRMY
$2.49B
$1.38M 0.35%
+50,100
New +$1.73M
1 2
3
4 5

Similar funds

KAS
Kemnay Advisory Services New York $791M AUM 14.14% 1-Year Est. Return
FSAG
Financial Solutions Advisory Group Chicago, Illinois $791M AUM
KAS
KPP Advisory Services Louisville, Kentucky $791M AUM 28.5% 1-Year Est. Return
BSSFA
Baron Silver Stevens Financial Advisors Boca Raton, Florida $791M AUM 18.81% 1-Year Est. Return
GUB
Golden Unicorn BVI Road Town $792M AUM 60.81% 1-Year Est. Return
EA
Enclave Advisors Austin, Texas $790M AUM 21.99% 1-Year Est. Return
BBES
Buffalo Business & Estate Services Orchard Park, New York $793M AUM
GEA
Glen Eagle Advisors Kingston, New Jersey $793M AUM 21.06% 1-Year Est. Return

Diadema Partners's Q3 2025 Portfolio in Review

As of Q3 2025, Diadema Partners held 170 positions worth $391M, up 19% from $328M the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Diadema Partners withdrew a net $30.5M in Q3 2025, closing 40 positions and reducing 22 holdings. Its most notable exit was Amgen, an estimated $14.5M position sold in full.

By sector, the portfolio is most concentrated in Miscellaneous at 63% of assets, up from 51% a quarter earlier, followed by Healthcare.

Against the trend, Diadema Partners opened a new position in Bristol-Myers Squibb worth $5.86M.

  • Diadema Partners's largest Q3 2025 buy was Bristol-Myers Squibb: 130,000 shares worth $5.86M.
  • Diadema Partners added most to Regeneron Pharmaceuticals in Q3 2025, an estimated $13.9M increase.
  • Diadema Partners's biggest Q3 2025 reduction was TG Therapeutics, cutting an estimated $10.2M.
  • Diadema Partners fully exited Amgen in Q3 2025, selling an estimated $14.5M.
  • Diadema Partners's ten largest holdings make up 31% of its $391M portfolio in Q3 2025.
  • Diadema Partners opened 75 new positions and closed 40 in Q3 2025.
  • Diadema Partners's portfolio value rose 19% quarter-over-quarter to $391M.

Based on Diadema Partners's 13F filing for Q3 2025, filed 14 Nov 2025.